Home > Boards > US Listed > Biotechs >

BioTime, Inc. (BTX)

BTX RSS Feed
Add BTX Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 5/20/2019 7:47:05 AM - Followers: 74 - Board type: Free - Posts Today: 0

 

BioTime, Inc.  (BTX)

 

 
 

 

http://www.biotimeinc.com/

 

 

 

Company Information:

BioTime, Inc.
1301 Harbor Bay Parkway
Alameda, CA 94502

Phone: 510-521-3390
      Fax: 510-521-3389

 

CIK

0000876343

 

 

BioTime, Inc. (NYSE AMEX: BTX) is a biotechnology company engaged in two areas of biomedical research and product development:

  • Stem cell technology and products for use in regenerative medicine.  These products and technologies are being developed and marketed by our wholly owned subsidiary Embryome Sciences, Inc.
  • Blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications.  Our lead product is Hextend® which is being marketed by Hospira, Inc. and CJ CheilJedang Corp. under exclusive licenses from us

 

The Potential of Regenerative Medicine

Regenerative medicine refers to therapies based on human embryonic stem ("hES") cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The great scientific and public interest in regenerative medicine lies in the potential of hES cells to transform into any cell type of the human body. hES cells therefore show considerable potential as a source of new therapies for a host of currently-incurable diseases such as: diabetes, stroke, Alzheimer's and Parkinson's disease, heart failure, arthritis, muscular dystrophy, spinal cord injury, macular degeneration, hearing loss, kidney and liver failure, as well as many other disorders that may be treated by replacing diseased or damaged organ tissues. In response to the unusual potential of the field, the State of California has allocated $3 billion over the next 10 years to fund basic research, and President Obama has lifted previous restrictions for federal funding of stem cell research.

Led by Dr. Michael West, considered by many to be a founding father of the stem cell industry, BioTime has assembled an array of products and associated intellectual property that give it the potential to be a leader in this exciting new field of medicine.

We are implementing a near-term revenues strategy in the regenerative medicine field by seeking to develop and market advanced hES products and technology that can be used by researchers at universities and biopharmaceutical companies. These research-only products generally can be marketed without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to human therapeutic products. We may also initiate development programs for human therapeutic applications if sufficient capital becomes available to us or through joint efforts with industry partners.

BioTime is leveraging its product development strategy on two key technology platforms:
 

  • • An advanced iPS technology allowing the transformation of human cells of the body back to a primordial stem cell state equivalent to embryonic stem cells. Using this technology with patient specific stem cells, rather than stem cells derived from embryos donated by unrelated people, may reduce the incidence of rejection of tissue grafts.
     
  • ACTCellerate™ technology that permits the generation of scalable and highly purified cells of the human body.

See this link for more information:  http://www.biotimeinc.com/aboutBT.htm

 

 

 

 

 

 

Management: 

http://www.biotimeinc.com/management.htm
 

 

Dr. Michael West, CEO

Dr. West is the Chief Executive Officer of BioTime, Inc. (NYSE AMEX: BTIM) and Embryome Sciences, Inc. of Alameda, California. The Companies are focused on developing an array of research and therapeutic products using human embryonic stem cell technology. He received his Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging. He has focused his academic and business career on the application of developmental biology to the age-related degenerative disease. He was the Founder of Geron Corporation of Menlo Park, California (Nasdaq: GERN) and from 1990 to 1998 he was a Director, and Vice President, where he initiated and managed programs in telomerase diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells. From 1995 to 1998 he organized and managed the research collaboration between Geron and its academic collaborators James Thomson and John Gearhart that led to the first isolation of human embryonic stem and human embryonic germ cells. From 1998 to 2007 he was President and Chief Scientific Officer at Advanced Cell Technology, Inc. (OTCBB: ACTC) where he managed programs in animal cloning, human somatic cell nuclear transfer, retinal differentiation, and ACTCellerate, a technology for the multiplex derivation and characterization of clonal human embryonic progenitor cell lines. 

Dr. West's complete CV and background on his research interests are available online at: http://www.michaelwest.org/


 

 

 

 

Recent News: 

http://www.b2i.us/profiles/investor/ResLibrary2.asp?BzID=1152&GoTopage=&Category=1802&t=
 

 

http://finance.yahoo.com/q/h?s=BTX+Headlines

 

Subsidiaries
http://www.biotimeinc.com/subsidiaries/


 

 

Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0000876343&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

 

 

Transfer Agent:

American Stock Transfer & Trust Company
59 Maiden Lane
New York 10038

 

Investor Relations:

Judith Segall

VP of Administration, Corporate Secretary

isegall@biotimemail.com

Phone:  510.521.3390 ext 301

 

 

 


 

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

Also, keep in mind that moderators may or may not have a position in said stock.   Being a moderator isn't a sign of endorsement.

  

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:
http://investorshub.advfn.com/boards/complex_terms.asp

 

BTX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BTX News: Statement of Changes in Beneficial Ownership (4) 05/22/2019 04:32:46 PM
BTX News: Initial Statement of Beneficial Ownership (3) 05/22/2019 04:30:29 PM
BTX News: BioTime Announces Appointment of General Counsel 05/22/2019 08:00:00 AM
BTX News: BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegenĀ® 05/10/2019 08:00:00 AM
BTX News: Current Report Filing (8-k) 05/10/2019 07:56:35 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#1163   AGE didn't specify which program(s) they were reducing bobby2loaves 05/20/19 07:47:04 AM
#1162   Thanks, bobby. I hadn't had time to review tradetrak 05/19/19 10:40:33 PM
#1161   OK - I went through the AGE quarterly bobby2loaves 05/18/19 08:09:03 AM
#1160   tradetrak, The 1/4ly wasn't too bad IMO but ahab333 05/17/19 11:59:05 AM
#1159   Anybody know why we're under so much pressure tradetrak 05/14/19 05:29:35 PM
#1158   This report came to my email from IR ahab333 04/26/19 11:56:01 AM
#1157   The big boys are increasing their stake here Cannabisprince 03/20/19 07:39:19 PM
#1156   End of the day though wallstreethustler 03/15/19 05:17:22 PM
#1155   Summary: we are establishing a new corporate Brand DeepDive 03/15/19 12:30:37 AM
#1154   4th Biotime Quarter & full 2018 financial reports --- ahab333 03/14/19 05:51:16 PM
#1153   DD, we will see about cashing burning ways ahab333 03/14/19 10:55:59 AM
#1152   BTX continues on its cash burning ways. DeepDive 03/11/19 11:21:52 AM
#1151   New on the Asterias/Biotime acquistion is now completed ahab333 03/11/19 11:07:35 AM
#1150   I too am waiting to hear if they ahab333 03/07/19 05:39:00 PM
#1149   Thanks, I saw the post. Let's hope Cincinnatus 03/07/19 03:54:05 PM
#1148   Cincinnatus, I just got an email that the ahab333 03/07/19 01:16:03 PM
#1147   BTX on or around March 21 techxen 02/18/19 03:43:16 PM
#1146   Anyone have a date for earnings call for Cincinnatus 02/12/19 01:07:44 PM
#1145   Very few posts reflects the very little material DeepDive 02/03/19 12:02:01 AM
#1144   Well, something they own 1/3 of announced positive pymadams 01/30/19 03:10:21 AM
#1143   so this is riding on the back of madras50 01/29/19 08:53:45 PM
#1142   * * $BTX Video Chart 01-29-2019 * * ClayTrader 01/29/19 05:49:32 PM
#1141   see POST #1135 for whats moving the ahab333 01/29/19 01:18:17 PM
#1140   Nvm, I found this article: https://www.streetinsider.com/Corporate+News/BioTime+ HonTer 01/29/19 01:08:41 PM
#1139   Thanks for that info. I hadn't seen it tradetrak 01/29/19 01:06:51 PM
#1138   Why is that? Is that because BTX owns HonTer 01/29/19 12:49:17 PM
#1137   I am also wondering what's the news behind HonTer 01/29/19 12:33:13 PM
#1136   Thanks pymadams, I forgot all about that with ahab333 01/29/19 12:02:25 PM
#1135   The rise is likely due to the good pymadams 01/29/19 11:32:21 AM
#1134   Over 2 million shares in 1 1/4 hours ahab333 01/29/19 10:44:27 AM
#1133   Work in progress with Opregen & Orbit's device. ahab333 01/07/19 01:04:05 PM
#1132   Just noticed that in the last 9 days, ahab333 01/07/19 12:31:43 PM
#1131   We are still here, though, we feel BTXs DeepDive 12/29/18 12:20:53 PM
#1130   bobby2loaves, that could be a dire outlook for ahab333 12/24/18 10:52:08 AM
#1129   Hey Ahab, I still visit this site. bobby2loaves 12/23/18 09:37:00 AM
#1128   More volume than I have seen in one ahab333 12/21/18 03:19:20 PM
#1127   The current report filing gives some indication of pymadams 12/20/18 09:10:12 AM
#1126   Yet another all time low for BTX, 1.07. ahab333 12/17/18 02:58:11 PM
#1125   From Yahoo msg. board an hour ago. Cincinnatus 12/10/18 06:01:57 PM
#1124   The latest presentation shows some new (to us) pymadams 12/10/18 05:20:19 AM
#1123   Hystem making progress in the preclinical environment: ahab333 12/04/18 03:11:25 PM
#1122   Thanks Bobby. I actually was there yesterday ahab333 11/30/18 01:56:13 PM
#1121   It's right here: https://investorshub.advfn.com/boards/board.aspx?board_id=214 bobby2loaves 11/30/18 10:49:51 AM
#1120   Does anyone know if there is a message ahab333 11/30/18 09:54:09 AM
#1119   No problem Family, as you can see it's ahab333 11/29/18 09:47:18 AM
#1118   Oops. I did not read far enough... thefamilyman 11/28/18 08:00:19 PM
#1117   Since AGEX is not publicly traded, does anyone thefamilyman 11/28/18 07:59:05 PM
#1116   News BioTime Announces Distribution of AgeX Therapeutics Shares ahab333 11/28/18 09:39:21 AM
#1115   Cincinattus asked: Anyone have a prediction as bobby2loaves 11/12/18 07:11:00 PM
#1114   Anyone have a prediction as to what the Cincinnatus 11/12/18 05:09:49 PM
PostSubject